BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica

BeiGene Ltd said on Monday a late-stage trial testing its recently approved cancer treatment Brukinsa did not meet the main goal of proving superior to Imbruvica, a rival medicine from Johnson & Johnson and AbbVie Inc.